ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 79 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $35,961 | +11.6% | 6,309 | +15.3% | 0.00% | – |
| Q4 2022 | $32,236 | -25.0% | 5,473 | -59.6% | 0.00% | – |
| Q3 2022 | $43,000 | -28.3% | 13,563 | +1.1% | 0.00% | – |
| Q2 2022 | $60,000 | -85.1% | 13,416 | -82.3% | 0.00% | -100.0% |
| Q1 2022 | $404,000 | +797.8% | 75,599 | +3424.4% | 0.00% | +200.0% |
| Q3 2021 | $45,000 | -76.9% | 2,145 | -80.5% | 0.00% | -50.0% |
| Q2 2021 | $195,000 | +490.9% | 11,024 | +716.6% | 0.00% | – |
| Q1 2021 | $33,000 | -90.8% | 1,350 | -87.3% | 0.00% | -100.0% |
| Q2 2020 | $357,000 | – | 10,598 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |